How to Compare GTM Performance Across a Portfolio When Every Company Speaks a Different Revenue Language

The question this answers

Leadership teams across my portfolio bring completely different numbers, definitions, and narratives to every board meeting. What's the minimum viable set of commercial KPIs I can mandate across all portcos without creating a compliance nightmare?

By , Founding Partner, Humus & Shore

PE operating partners can't compare GTM across a portfolio when every company tracks different metrics. Here's the governance framework that fixes it.

How to Compare GTM Performance Across a Portfolio When Every Company Speaks a Different Revenue Language

More than 18,000 portfolio companies are stuck beyond traditional hold periods. LPs are asking harder questions about value creation. And GTM — the function most responsible for revenue — is still the least instrumented and least comparable capability across most portfolios.

Every portfolio company has a different CRM configuration. A different definition of a qualified opportunity. A different story for why the pipeline number means what it means.

That's not a data problem. It's a governance problem.

The Root Cause: No Common Language

At the company level it looks like this: one team calls anything with a signed NDA a qualified lead. Another requires a scoped proposal before moving a deal to the same stage. A third tracks ARR in a spreadsheet that lives in the CFO's inbox.

When you try to compare pipeline health or conversion efficiency across those three companies, you're not comparing data — you're comparing opinions.

This isn't a criticism of portfolio company leadership. It's a predictable outcome of building companies in isolation. The problem surfaces when you need to answer a board question about where commercial risk is concentrated.

Why 100-Day Plans Don't Fix This

The instinct is to install a new CRM, hire a VP of Sales, or launch a campaign. I understand the instinct — when you're under pressure to show progress, visible action feels like progress.

But none of those moves produce comparable data at the portfolio level. And none of them surface the actual constraint — which might be ICP definition, pricing architecture, or a sales motion misaligned with how the buyer actually makes decisions.

Acceleration before diagnosis is how you burn runway on the wrong lever. The new VP of Sales inherits a pipeline full of deals that were never real, hits the ground running, and six months later the board is asking why nothing closed.

What Comparability Actually Requires

Take the portfolio-level claims here as directional, not proven. I haven't deployed this across a portfolio; it's a hypothesis about how a company-level GTM diagnostic scales to portfolio comparability.

Here's what I think it requires:

A shared diagnostic instrument. Before you can compare performance, you need a common assessment framework applied consistently across portfolio companies — one that scores commercial readiness against the same criteria regardless of company size, sector, or CRM vendor. It should produce a scored output you can bring into a portfolio review. Whether you buy it or build it internally, the principle is the same: you need a rubric, not a narrative.

Standardized ICP definitions. A common source of pipeline inflation is an undefined or inconsistently applied Ideal Customer Profile. When every company defines its target customer differently, win-rate comparisons are meaningless and churn attribution is guesswork. A common schema for ICP documentation — even if the underlying profiles differ by vertical — gives you a foundation for comparing commercial efficiency.

A value-creation roadmap that names the mechanism. 'Grow revenue' is not a plan. A defensible roadmap names the specific commercial bottleneck, the intervention, the leading indicator that confirms the intervention is working, and the timeline. That structure makes it possible to compare progress across portfolio companies without requiring a bespoke narrative from each CEO.

The AI Question

Funds are building AI capability at the platform level. Most portfolio companies are not yet instrumented to benefit from it. If your portfolio companies can't produce clean, comparable GTM data today, AI tooling at the fund level will analyze noise, not signal.

Comparability is the prerequisite for AI leverage, not the output of it. That's not a sales pitch — it's a sequencing problem.

Three Moves, In Order

Run a diagnostic before you prescribe. Apply a structured assessment to every portfolio company before the 100-day plan is written. Score ICP clarity, pipeline stage integrity, conversion visibility, and retention instrumentation on a common rubric. The output tells you where commercial risk is concentrated and what type of intervention is warranted.

Standardize the schema, not the stack. You can't force every portfolio company onto the same CRM. You can require that every portfolio company maps its existing stages to a common definitional schema — so that 'Stage 3' at Company A and 'Proposal Sent' at Company B mean the same thing in your portfolio dashboard. This is a governance decision, not a technology project.

Make GTM artifacts portable. ICP definitions, persona libraries, and value-creation roadmaps should be documented in a format that survives leadership turnover and travels into board packages without translation. If the commercial strategy lives only in the head of the current VP of Sales, it's not an operating asset — it's a retention risk.

If you're an operating partner working on the portfolio-level version of this problem, I'd like to hear where this framework breaks down at your scale.

Sources

  1. 84% of PE fund managers report longer hold periods as 4,000+ US portfolio companies aged 5+ years await exit — LPs now demanding crisp value creation plan execution · bdo.com
  2. PE exit bottleneck at 20-year high: 18,000+ portfolio companies stuck beyond traditional hold periods, forcing operating partners to own value creation longer · insights.woozleresearch.com
  3. 100-day plans systemically fail because they assume revenue acceleration before diagnosing commercial bottlenecks — GTM Partners and Blue Ridge Partners both flag the same structural gap in 2025–2026 practitioner guides · gtmpartners.com
  4. FTI's 2026 PE AI Radar: 95% of fund AI initiatives are meeting or exceeding original business case — but only ~20% of portfolio companies have operationalised GenAI with measurable results · fticonsulting.com